Clinical trials open for the enrollment
Title: KRT232-117 – “An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)”
Study aimed to investigating the efficacy of KRT-232, an inhibitor of the MDM2 oncogene (which in turn inhibits the p53 tumor suppressor), in combination with a tyrosine kinase inhibitor normally used in Ph+ cronic myeloid leukemia.
Principal Investigator: Prof. Pierfrancesco Tassone
For enrollment information please contact: Dr. Luigia Gervasi (Tel: +39 0961-3647921) Email: luigiagervasi@gmail.com
Title: innovaTV207 – “Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors”
In this trial are investigated efficacy and safety of tisotumab vedotin, antbody- drugconjugate direct against tissutal factor, alone or in association with other drugs, in following neoplasms: colorectal, non-small cell lung cancer, exocrine pancrea, head and neck.
Principal Investigator: Prof. Pierfrancesco Tassone
For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Title: ARISE – “Acalabrutinib Real World Italian obSErvational Study”
Acalabrutinib is a second generation selective Bruton’s tyrosine kinase (BTK) inhibitor active in lymphatic cronic leukaemia. This is a real-world study, that in particular aims to evaluate in terms of discontinuation and time to discontinuation of treatment in a real life’s context.
Principal Investigator: Prof. Daniele Caracciolo
For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Title: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Phase 1/2 first-in-human trial that investigates role of BMS-986288 (a modified form of ipilimumab), alone or in association to nivolumab, in various tumors.
Principal Investigator: Prof. Pierfrancesco Tassone
For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Clinical trials closed for the enrollment
Title: LNA-i-miR-221 – “A dose escalation phase I study of LNA-i-miR-221 for the treatment of refractory multiple myeloma and advanced solid tumors”
Sponsor: Azienda Ospedaliero-Universitaria Mater Domini Catanzaro – Studio Clinico di Fase I spontaneo supportato da progetto AIRC 5×1000
Principal Investigator: Prof. Pierfrancesco Tassone